Capricor Therapeutics Faces Legal Challenge as Key Drug Trial Nears Completion

Legal Investigation Examines Alleged Disclosure Issues

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company’s future. The legal investigation, made public on October 28, 2025, emerges at what could be the most crucial moment for the biotechnology firm’s flagship treatment targeting Duchenne muscular dystrophy.

Kuehn Law has initiated legal proceedings in federal court, focusing on whether Capricor’s leadership may have breached fiduciary responsibilities. Central to the case are allegations that company insiders potentially provided investors with material information about the cell therapy Deramiocel while possibly disseminating inaccurate or misleading statements regarding four-year data from the Phase 2 HOPE-2 clinical study.